Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

Inclusion Criteria: * Abdominal obese patients with · * Waist circumference \> 102 cm in men and \>88 cm in women * Dyslipidemia consisting of : * Triglycerides ≥ 1.50 g/L (i.e 1.69 mmol/L) and ≤ 7.0 g/L(i.e. 7.90 mmol/L)AND/OR * HDL-cholesterol \< 50 mg/dL (i.e. 1.29 mmol/L) in women and \< 40 mg/dL (i.e. 1.04 mmol/L) in men Exclusion Criteria: * Pregnancy or lactation * Women of child-bearing potential with no medically approved contraception * Patients with type 1 diabetes * Patients with type 2 diabetes must be on a stable dose of oral antidiabetic drugs (excluding glitazones, exenatide, sulfonylurea and nateglinide) and should not receive insulin therapy * Patients with any clinically significant endocrine disease * Patients on anticoagulants (heparin, warfarin) or with bleeding disorders * Clinically relevant disease interfering with subject's safety or making implementation of the study protocol or interpretation of study results difficult * Patients with mental retardation or any clinically significant psychiatric disorder * History or concurrent substance abuse (other than nicotine or caffeine especially marijuana or hashish) * Chronic systemic corticotherapy * Patients with weight change \> 5kg within 3 months prior to screening * Patients should not have received anti-obesity drugs or other drugs for weight reduction in the 3 months prior to screening. * The investigator will evaluate whether there are other reasons why a patient may not participate